Recruiting Efficacy and Safety of Dalpiciclib Combined With Endocrine Adjuvant Therapy for Early HR +/HER2- Breast Cancer: a Multicenter, Prospective Clinical Study NCT07581834 Conditions Breast Diseases, Breast Neoplasms, CDK4/6 Inhibitor, +7 more Locations Fujian Cancer Hosptial — Fuzhou, Fujian, China West China Hospital of Sichuan University — Chengdu, Sichuan, China View Trial Details
